TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10777036

Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg three times daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (1 mL/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prazosin with alcohol ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 10
Study: 8876513

Group type: EXPERIMENTAL
Intervention: High protein‐energy supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protein‐energy supplement (nonsupplemented children)
Number of subjects: 0
Study: 2142323

Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient treatment for 4-6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 74141

Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy with low doses of Vinblastine and subsequent chemotherapy based on 99m‐Tc ‐‐labelled Bleomycin uptake
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chemotherapy based on individual Tc‐Bleomycin uptake curves
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chemotherapy in 23 patients with previously untreated T3 tumors
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chemotherapy overall
Number of subjects: 61
Study: 30496532

Group type: EXPERIMENTAL
Intervention: Capacity enhancement intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 65
Study: 31070471

Group type: EXPERIMENTAL
Intervention: High-intensity rosuvastatin
Number of subjects: 11269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11269
Study: 28434097

Group type: EXPERIMENTAL
Intervention: Complementary/integrative medicine (CIM) treatments
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no IP consultation)
Number of subjects: 205
Study: 25984802

Group type: EXPERIMENTAL
Intervention: Modular EBT
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard EBT
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 145
Study: 23958407

Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g as calcium carbonate)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 (800 IU)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g as calcium carbonate) and Calcium plus vitamin D3 (800 IU) pooled
Number of subjects: 92
Study: 21752880

Group type: EXPERIMENTAL
Intervention: MBX-8025 (50 or 100 mg)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: MBX-8025 (50 or 100 mg) combined with atorvastatin (20 mg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 19635616

Group type: EXPERIMENTAL
Intervention: Bazedoxifene/conjugated estrogens (BZA/CE)
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Raloxifene (60 mg)
Number of subjects: 3397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study: 22707560

Group type: EXPERIMENTAL
Intervention: Fish oil (9 g/day; 1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (olive oil; 9 g/day)
Number of subjects: 67
Study: 15696983

Group type: EXPERIMENTAL
Intervention: 5-ALA + IPL
Number of subjects: 10

Group type: COMPARATOR
Intervention: IPL
Number of subjects: 10
Study: 12592236

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol combinations (0/5, 0.25/5, 1/5, 0/10, 0.5/10, or 1/10)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: 1/5 norethindrone acetate/ethinyl estradiol
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Other norethindrone acetate/ethinyl estradiol combinations
Number of subjects: 945

Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens/2.5 mg medroxyprogesterone acetate
Number of subjects: 945
Study: 10319056

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms b.i.d.
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms q.i.d.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 8568002

Group type: EXPERIMENTAL
Intervention: Skin puncture blood
Number of subjects: 32

Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 32
Study: 2569996

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine administered three times daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 mg hydroxyzine administered three times daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 21
Study: 383108

Group type: EXPERIMENTAL
Intervention: 200 mg indoprofen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 250 mg naproxen
Number of subjects: 18
Study: 29926357

Group type: EXPERIMENTAL
Intervention: Preperitoneal bupivacaine 0.5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study: 27010144

Group type: EXPERIMENTAL
Intervention: Early blood purification therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 32
Study: 25566930

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg (on-dialysis)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg (off-dialysis)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 10
Study: 24384954

Group type: EXPERIMENTAL
Intervention: Posterolateral mini-incision total hip arthroplasty (Group A)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional posterolateral incision total hip arthroplasty (Group B)
Number of subjects: 94
Study: 20199985

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract supplements (average of 82 mg/day for 6-12 months)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1240
Study: 17997115

Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol via pMDI+ Volumatic
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 mcg salbutamol via pMDI+ Volumatic
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol via Diskus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 mcg salbutamol via Diskus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Finney method
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Emax method
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 18

Group type: COMPARATOR
Intervention: pMDI+ Volumatic
Number of subjects: 18
Study: 16203593

Group type: EXPERIMENTAL
Intervention: CTG + ST (fetal ECG waveform analysis combined with cardiotocography)
Number of subjects: 4966

Group type: COMPARATOR
Intervention: CTG only (control group)
Number of subjects: 4966
Study: 12887140

Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10505460

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 8607726

Group type: EXPERIMENTAL
Intervention: Warfarin (target prothrombin time ratio, 1.3 to 1.8; approximate international normalized ratio, 2.0 to 4.5)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily, enteric coated)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or younger receiving anticoagulation
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Patients older than 75 years receiving anticoagulation
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or younger
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Patients older than 75 years
Number of subjects: 1100
Study: 2019027

Group type: EXPERIMENTAL
Intervention: Pirmenol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 18
Study: 6101151

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide oral solution (500 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide tablets (500 mg)
Number of subjects: 6
Study: 31149737

Group type: EXPERIMENTAL
Intervention: Version 5.0 CAHPS survey
Number of subjects: 3720

Group type: COMPARATOR
Intervention: Version 4.0 CAHPS survey
Number of subjects: 3720
Study: 28591763

Group type: EXPERIMENTAL
Intervention: Ethanol 18 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol 30 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol 6 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol 12 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol 24 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ethanol 42 g
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26396030

Group type: EXPERIMENTAL
Intervention: Perihematomal edema (PHE) volume expansion in the first 72 hours (iPHE)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for basal ganglia ICH and small (<30 mL) ICH
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Absolute increase in PHE during 72 hours
Number of subjects: 596
Study: 23408163

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reviews
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (no pharmacist-led medication reviews)
Number of subjects: 369
Study: 21251307

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 59
Study: 19336424

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 60
Study: 17575493

Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF) denervation (80 degrees C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) denervation (2 Hz)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local anesthetic (Control group)
Number of subjects: 60
Study: 15234143

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (250 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 1%
Number of subjects: 76

Group type: COMPARATOR
Intervention: All treated (acetazolamide and apraclonidine) vs. nontreated
Number of subjects: 76
Study: 10710072

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS) with placebo (3-5 ml of ethanolamine oleate per varix and placebo injection at 50 microg/h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (EVS) with octreotide (50 microg/h continuously for 5 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS) with placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (EVS) with octreotide
Number of subjects: 70
Study: 9029451

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling with the aerosol reduction device for 5 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ultrasonic scaling without the aerosol reduction device for 5 minutes
Number of subjects: 12
Study: 8458451

Group type: EXPERIMENTAL
Intervention: 1.25 mg gestrinone two times per week for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5 mg gestrinone two times per week for 6 months
Number of subjects: 20
Study: 3753671

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspirin with sucralfate
Number of subjects: 12
Study: 29808523

Group type: EXPERIMENTAL
Intervention: Robot-assisted training (RAT) plus physical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Physical therapy only (Control)
Number of subjects: 48
Study: 26643930

Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 700

Group type: COMPARATOR
Intervention: tOPV
Number of subjects: 700
Study: 25151920

Group type: EXPERIMENTAL
Intervention: Dual-energy coronary CT angiography (DECT) with 35 mL iodinated contrast
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard iodinated contrast volume coronary CT angiography (SCCTA) with 80 mL iodinated contrast
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dual-energy coronary CT angiography (DECT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard iodinated contrast volume coronary CT angiography (SCCTA)
Number of subjects: 102
Study: 22438429

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Distal references
Number of subjects: 186

Group type: COMPARATOR
Intervention: Attenuated plaque at baseline
Number of subjects: 186
Study: 19422648

Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: High FNE children
Number of subjects: 502
Study: 19278087

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare FlexCare)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rotation-oscillation toothbrush (Oral-B Triumph)
Number of subjects: 48
Study: 15970946

Group type: EXPERIMENTAL
Intervention: Muscular strength training (group A) for 3 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-strengthening exercises (group B) for 3 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Comparison between group A and group B at postoperative day 7
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Nutritional intake
Number of subjects: 119
Study: 12028504

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg day-1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg day-1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 165

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 165
Study: 10225583

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 32
Study: 9291741

Group type: EXPERIMENTAL
Intervention: 1% oxytetracycline eye drops combined with a specific health education programme
Number of subjects: 1810

Group type: EXPERIMENTAL
Intervention: Health education programme only
Number of subjects: 1810

Group type: EXPERIMENTAL
Intervention: Mass treatment only
Number of subjects: 1810

Group type: COMPARATOR
Intervention: No intervention (control village)
Number of subjects: 1810
Study: 2195516

Group type: EXPERIMENTAL
Intervention: TDX method of determination
Number of subjects: 8

Group type: COMPARATOR
Intervention: EMIT method of determination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow-release preparations of theophylline
Number of subjects: 8
Study: 37862

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg kg‐1
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 145
Study: 31518175

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553

Group type: COMPARATOR
Intervention: Routine Surveillance (RS)
Number of subjects: 553
Study: 29978375

Group type: EXPERIMENTAL
Intervention: 2000 IU Cholecalciferol drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28120591

Group type: EXPERIMENTAL
Intervention: Oral indomethacin (0.2 mg/kg daily for 3 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10, 5, 5 mg/kg every 24 hours for 3 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study: 23471762

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 22583636

Group type: EXPERIMENTAL
Intervention: Zibotentan
Number of subjects: 2577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2577
Study: 20061726

Group type: EXPERIMENTAL
Intervention: Test lotion containing niacinamide, panthenol, and tocopheryl acetate applied daily for 10 weeks
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control lotion applied daily for 10 weeks
Number of subjects: 246
Study: 16777318

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 70
Study: 16261463

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (0.5, 1.0, and 1.5 MAC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.5, 1.0, and 1.5 MAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (patients awake after surgery)
Number of subjects: 30
Study: 11985406

Group type: EXPERIMENTAL
Intervention: High-fiber foods (4 servings/day) plus telephone-based support service
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (handout describing NCEP Step-1 diet)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 10321168

Group type: EXPERIMENTAL
Intervention: OsteoGraf/N alone or with autogenous bone and/or demineralized freeze-dried bone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with demineralized freeze-dried bone allograft
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with intraoral autogenous bone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with expanded polytetrafluoroethylene membrane
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sinus elevation procedure
Number of subjects: 113
Study: 7654805

Group type: EXPERIMENTAL
Intervention: Traditional extension exercises of the spine (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Extension exercises and exercises to stretch and strengthen scapular musculature (group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study: 2576362

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (2 mg o.d., loading dose = 2 b.i.d. over the first three days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride
Number of subjects: 20
Study: 788143

Group type: EXPERIMENTAL
Intervention: Meningococcal group A polysaccharide vaccine
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Haemophilus influenzae type b polysaccharide vaccine
Number of subjects: 100000
Study: 6259981

Group type: EXPERIMENTAL
Intervention: Prophylactic leukocyte transfusions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (no leukocyte transfusions or only therapeutic leukocyte transfusions)
Number of subjects: 58
Study: 31702469

Group type: EXPERIMENTAL
Intervention: Mendelian Randomization (MR) methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional epidemiological studies
Number of subjects: 0
Study: 29617066

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 26940369

Group type: EXPERIMENTAL
Intervention: Computerized touch screen decision aid (CDA; n=33)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Literacy appropriate print tool (PT; n=28)
Number of subjects: 61
Study: 24500238

Group type: EXPERIMENTAL
Intervention: Standard or high-dose infusions of normal saline
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: High-volume hydration
Number of subjects: 592

Group type: COMPARATOR
Intervention: Control group (standard hydration)
Number of subjects: 592
Study: 23001778

Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries
Number of subjects: 168

Group type: COMPARATOR
Intervention: Ovulation induction with gonadotrophins (recombinant FSH)
Number of subjects: 168
Study: 21054884

Group type: EXPERIMENTAL
Intervention: Standardised clinical management pathway (specialist starts clinical pathway within 2 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (existing care until review by specialist at 6 weeks)
Number of subjects: 250
Study: 17308327

Group type: EXPERIMENTAL
Intervention: Vitamin D(3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15569397

Group type: EXPERIMENTAL
Intervention: Left 3 Hz rTMS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Right 3 Hz rTMS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Left 10 Hz rTMS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Right 10 Hz rTMS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Clomipramine with sham rTMS
Number of subjects: 59
Study: 12140629

Group type: EXPERIMENTAL
Intervention: Pistol-grip handles (PGH)
Number of subjects: 46

Group type: COMPARATOR
Intervention: In-line handles (ILH)
Number of subjects: 46
Study: 9865813

Group type: EXPERIMENTAL
Intervention: High structured treatment
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low structured treatment
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Noncompliance group
Number of subjects: 119
Study: 8929930

Group type: EXPERIMENTAL
Intervention: Case management only (n = 96)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Case management with supported housing (n = 136)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control condition (n = 187)
Number of subjects: 419
Study: 2649197

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 100